- Mahmud N, Molloy A, McPartlin J, Corbally R, Whitehead AS, Scott JM, et al. Increased prevalence of methylenetetrahydro folate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Gut 1999;45:38994.
- Nielsen JN, Larsen TB, Fredholm L, Brandslund I, Munkholm P, Hey H. Increased prevalence of methylenetetrahydrofolat e reductase C677T variant in patients with IBD [Letter]. Gut 2000; 47:456-7.
- Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a commom mutation in methylenetetrahydrofolat e reductase. Nat Genet 1995:10:111-3.
- Makris M. Hypemomocysteinemi a is a risk factor for venous and arterial thrombosis. Br J Haematol 1998;101 Suppl 1:18-20, 18-20.
- Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
- Graham IM, DaIy LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. European Conceited Action Project. JAMA 1997:277:1775-81.
- Kjeldsen J, Lassen JF, Brandslund I, Schaffalitzky de Muckadel l OB. Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease. Scand J Gastroenterol 1998;33:637-43.
- Haslam N, Standen GR, Probert CS. An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999;11:1289-91.
- Helio T, Wartiovaara U, Halme L, Turunen UM, Mikkola H, Palotie A, et al. Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:170-4.
- Koutroubakis IE, Sflridaki A, Mouzas IA, Maladaki A, Kapsoritakis A, Roussomoustakaki M, et al. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2000:95:190-4.
- Over HH, Ulgen S, Tuglular T, Tezel A, Avsar E, Geyik G, et al. Thrombophilia and inflammatory bowel disease: does factor V mutation have a role? Eur J Gastroenterol Hepatol 1998;10: 827-9.
- Larsen TB, Lassen JF, Brandslund I, Byriel L, Bruun Petersen G, N0rgaard-Pedersen B. The Arg506Gln mutation (FV-Leiden) among a cohort of 4,188 unselected Danish newboms. Thromb Res 1998:89:211-5.
- Gaustadnes M, Rudiger N, Moller J, Rasmussen K, Larsen TB, Ingerslev J. Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. Blood Coagul Fibrinol 1999:10:251-9.
- Brandslund I, Teisner B, Hyltoft PP, Svehag SE Development and clinical application of electroimmunoassay s for the direct quantification of the complement C3 split products C3c and C3d. Scand J Clin Lab Invest Suppl 1984:168:57-73.
- Rasmussen K, Moller J, Lyngbak M. Within-person variation of plasma homocysteine and effects of posture and tourniquet application. Clin Chem 1999:45:1850-5.
- Larsen TB, Lassen JF, Dahler-Eriksen B, Petersen PH, Brandslund I. Effect of anticoagulant therapy on the hypercoagulable state in patients carrying the factor V Arg506Gln mutation. Thromb Res 1998:92157-62.
- Vila N, Reverter JC, Yague J, Chamorro A. Interaction between interleukin-6 and the natural anticoagulant system in acute stroke. J Interferon Cytokine Res 2000:20:325-9.
Scandinavian Journal of Gastroenterology
Volume 37, 2002 - Issue 1